The significant outperformance of Vertex Pharmaceuticals over the past decade, as highlighted by its average annual return of 19.19% and growth of a $1000 investment into $6,036.05, underscores the company's strong market position and potential for continued growth. This historical performance, coupled with a substantial market capitalization, suggests a positive outlook for VRTX in the short term, attracting investor interest and potentially driving up its stock price.